Philogen Aktie - PHIL

Professionelle Tools für Privatanleger.

Premium

Current Price

19,45

Gebot

19,45

Fragen

19,85

Volumen

2.201

19,50 Tagesbereich 19,95

16,50 52-Wochen-Bereich 21,90

Marktkapitalisierung

785,733M

Handelsende

20,00

Handelsbeginn

19,95

Letzte Trade

19.45

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

7.661

Ausgegebene Aktien

40.397.605

Dividendenrendite

Kurs-Gewinn-Verhältnis

0,00

Gewinn pro Aktie (EPS)

Erlöse

25,12M

Nettogewinn

-6,16M

Sektor

Pharmaceutical Preparations

Branche

Pharmaceutical Preparations

Website

www.philogen.com

Hauptsitz

Siena, Siena, Ita

Gegründet

Philogen Spa is listed in the Pharmaceutical Preparations sector of the Italienische Börse with ticker PHIL. The last closing price for Philogen was 20,00 €. Over the last year, Philogen shares have traded in a share price range of 16,50 € to 21,90 €.

Philogen currently has 40.397.605 shares in issue. The market capitalisation of Philogen is 807,95 € million.

Philogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients with first-line advanced or metastatic Soft Tissue Sarcoma

Philogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients...

Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by Competent Authorities

Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by...

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for...

Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma

Intratumoral Nidlegy™ followed by surgery significantly improved the Recurrence-Free Survival compared to...

Philogen Announces Clinical Trial Collaboration with MSD

Philogen Announces Clinical Trial Collaboration with MSD The Phase II clinical trial investigates Philogen's immunocytokines (i) L19IL2 (ii...

Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand

Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in...

Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital Zürich

Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University...

Philogen Announces Publication of a New Study in Collaboration with Google focused on Machine Learning models applied to DNA-Encoded Chemical Library Technology

Philogen Announces Publication of a New Study in Collaboration with Google focused on Machine Learning models applied to DNA-Encoded Chemical...

Philogen Provides Corporate Update

Philogen Provides Corporate Update Philogen Provides Corporate Update Nidlegy™ and Fibromun pivotal clinical trials on track Fibromun shows...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-0.25	-1.26903553299	19.7	20	18.95	16487	19.75406997	DE
4	0.8	4.28954423592	18.65	20	17.8	10982	19.18496856	DE
12	0.6	3.18302387268	18.85	20	16.5	7661	18.61459471	DE
26	-0.75	-3.71287128713	20.2	21.3	16.5	6198	18.98108084	DE
52	2.15	12.4277456647	17.3	21.9	16.5	8221	19.4035117	DE
156	6.17	46.4608433735	13.28	21.9	13	8491	17.25116285	DE
260	2.45	14.4117647059	17	21.9	12.6	11827	16.12059437	DE

PHIL - Frequently Asked Questions (FAQ)

What is the current Philogen share price?

The current share price of Philogen is 19,45 €

How many Philogen shares are in issue?

Philogen has 40.397.605 shares in issue

What is the market cap of Philogen?

The market capitalisation of Philogen is EUR 807,95M

What is the 1 year trading range for Philogen share price?

Philogen has traded in the range of 16,50 € to 21,90 € during the past year

What is the reporting currency for Philogen?

Philogen reports financial results in EUR

What is the latest annual turnover for Philogen?

The latest annual turnover of Philogen is EUR 25,12M

What is the latest annual profit for Philogen?

The latest annual profit of Philogen is EUR -6,16M

What is the registered address of Philogen?

The registered address for Philogen is PIAZZA LA LIZZA, 7, SIENA, SIENA, 53100

What is the Philogen website address?

The website address for Philogen is www.philogen.com

Which industry sector does Philogen operate in?

Philogen operates in the PHARMACEUTICAL PREPARATIONS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
WAAT26AA Tech SpA	0,05 € (42,86%)	20k
WNUS26Nusco Spa	0,109 € (27,34%)	500
NTWNetweek SpA	0,0338 € (19,01%)	2,11M
FDAFidia	0,0044 € (15,79%)	10,83M
1BBVABanco Bilbao Vizcaya Argentaria SA	12,68 € (11,23%)	1.000
WBELLBellini Nauttica Spa	0,0038 € (-71,21%)	123,6k
S3GAXASolid World Group spa	0,0094 € (-51,79%)	717,21k
WHIK26Haiki Spa	0,0255 € (-49,00%)	4,13k
WS3D25Solid World Group spa	0,025 € (-24,47%)	19,44k
WINC26Innovatec SpA	0,0505 € (-22,90%)	1,72k
TITTelecom Italia SpA	0,319 € (1,27%)	399,89M
ISPIntesa Sanpaolo Spa	4,451 € (-7,05%)	114,72M
SPMSaipem Spa	1,9485 € (-8,44%)	85,44M
ENELEnel Spa	7,80 € (2,94%)	58,58M
STLAMStellantis NV	9,411 € (-7,66%)	35,99M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Philogen Spa (PHIL)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Über Philogen Spa

PHIL Neueste Nachrichten

Philogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients with first-line advanced or metastatic Soft Tissue Sarcoma

Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by Competent Authorities

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors

Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma

Philogen Announces Clinical Trial Collaboration with MSD

Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand

Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital Zürich

Philogen Announces Publication of a New Study in Collaboration with Google focused on Machine Learning models applied to DNA-Encoded Chemical Library Technology

Philogen Provides Corporate Update

PHIL - Frequently Asked Questions (FAQ)

Beweger

PHIL Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Philogen Spa (PHIL) Börsenkurse

Philogen Spa (PHIL)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Über Philogen Spa

PHIL Neueste Nachrichten

Philogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients with first-line advanced or metastatic Soft Tissue Sarcoma

Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by Competent Authorities

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors

Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma

Philogen Announces Clinical Trial Collaboration with MSD

Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand

Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital Zürich

Philogen Announces Publication of a New Study in Collaboration with Google focused on Machine Learning models applied to DNA-Encoded Chemical Library Technology

Philogen Provides Corporate Update

PHIL - Frequently Asked Questions (FAQ)

Beweger

PHIL Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen